| Heading: |
Abiraterone |
| Question ID: |
1809059 |
| UIN: |
HL8078 |
| House: |
Lords |
| Date tabled: |
2025-06-03 |
| Asking Member ID: |
1796 |
| Asking Member display name: |
Lord Taylor of Warwick
|
| Asking Member handle: |
Lord_ofWarwick
|
| Asking Member Twitter reference: |
@Lord_ofWarwick
|
| Member interest: |
false |
| Question text: |
To ask His Majesty's Government what assessment they have made of the use of artificial intelligence in the identification of patients with prostate cancer who would benefit most from treatment with abiraterone. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
347 |
| Answering Member display name: |
Baroness Merron
|
| Answering Member handle: |
|
| Answering Member Twitter reference: |
Baroness Merron
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
We are committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including artificial intelligence (AI) where it is benefi... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |